

Substitute for form 1449A/PTO

ATTORNEY'S DKT NO. 032475-007	APPLICATION NO. 10/051,243
APPLICANT Maurice ISRAËL et al.	
FILING DATE JANUARY 22, 2002	GROUP UNASSIGNED

INFORMATION DISCLOSURE ~~STATEMENT~~ BY APPLICANT

FER 2002

ENT TRADEMARK

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	MATTEI et al., "Naftazone reduces glutamate cerebro spinal fluid levels in rats and glutamate release from mouse cerebellum synaptosomes," <i>Neuroscience Letters</i> , 1999, pp. 183-86, vol. 271, Elsevier Science Ireland Ltd., Ireland.
	AZZA et al., "Lipid Peroxidation and Lysosomal Integrity in Different Inflammatory Models in Rats: The Effects of Indomethacin and Naftazone," <i>Pharmacological Research</i> , 1995, pp. 279-85, The Italian Pharmacological Society, Italy.
	ZICOT, "Etude multicentrique de l'efficacite et de la tolerance de la naftazone (Mediaven® 10 MG). Comparaison de deux schemas posologiques," <i>Revue Medicale De Liege</i> , April, 1993, pp. 224-28, France.
	HERBER et al., "Reduction and Glucuronidation of Naftazone by Human and Rat Liver Microsomes," <i>Drug Metabolism and Disposition</i> , 1995, pp. 1305-14, Vol. 23, No. 12, The American Society for Pharmacology and Experimental Therapeutics, Bethesda, Maryland, USA.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

(05/01)